hotspot -WSS

hotspot

author：fashion 2025-09-03 18:35:56 - browse：9879

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： ACIP vaccine advisory panel sees its vacancies filled

explore

leisure time

WSS

Problems with a popular proposal to regulate AI in health care

Bernie Sanders gets little from pharma CEOs on drug prices

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Juul documents reveal insider tactics on political lobbying

Artificial intelligence use in health care faces greater scrutiny in 2024

Report cites 'urgent' need to recruit more diverse clinical trial participants

knowledge

hotspot

focus

Drug repurposing or repositioning? The language matters

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Malaria cases in Florida and Texas: Here’s what you need to know

Global cancer cases to surge 77% by 2050, WHO report says

Sports medicine is finally prioritizing gender equality

Why Eli Lilly’s earnings didn’t quite live up to the hype

Medical records are filled with copy

Tome Biosciences co

Alkermes shareholders re

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

hotspot

Ebola vaccine can save some who are already sick, per new study

AstraZeneca stays mum on Medicare drug pricing negotiations

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Websites selling Wegovy, Zepbound ingredients targeted by FDA

AI gets buy

Tome Biosciences co

explore

hotspot

leisure time

entertainment